Biolase, Inc. short interest in 2022
In 2022, Biolase, Inc.'s disclosed short interest ran from 3.84% of shares outstanding on 14 Jan 2022 to 9.10% on 30 Dec 2022, a change of +5.26 percentage points. The year's high was 9.80% on 15 Dec 2022 and its low 1.60% on 31 Aug 2022, averaging 3.48% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.88 days on 14 Apr 2022. Full history: Biolase, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023
2022 in figures
- Start of year
- 3.84% (14 Jan 2022)
- End of year
- 9.10% (30 Dec 2022)
- Change
- +5.26 pp
- High
- 9.80% (15 Dec 2022)
- Low
- 1.60% (31 Aug 2022)
- Average
- 3.48%
- Highest days to cover
- 6.88 (14 Apr 2022)
- SEC filings marked
- 9
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 3.84% | 2.60 | results (8-K) |
| 31 Jan 2022 | 3.54% | 3.57 | |
| 15 Feb 2022 | 2.89% | 4.07 | |
| 28 Feb 2022 | 3.30% | 4.97 | |
| 15 Mar 2022 | 2.74% | 4.42 | |
| 31 Mar 2022 | 3.13% | 3.24 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 3.18% | 6.88 | |
| 15 Aug 2022 | 2.10% | 2.78 | 10-Q filed, results (8-K), 10-Q filed, results (8-K) |
| 31 Aug 2022 | 1.60% | 2.85 | |
| 15 Sep 2022 | 1.70% | 3.30 | |
| 30 Sep 2022 | 1.80% | 5.01 | |
| 14 Oct 2022 | 1.89% | 4.62 | |
| 31 Oct 2022 | 1.85% | 6.42 | |
| 15 Nov 2022 | 1.92% | 2.01 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 4.70% | 1.00 | |
| 15 Dec 2022 | 9.80% | 3.00 | |
| 30 Dec 2022 | 9.10% | 4.62 |
See also: Biolase, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.